first_imgAlthough it sounds like a case of gender confusion on a molecular scale, the male hormone androgen spurs the growth of some breast tumors in women. In a new study, Harvard scientists at Dana-Farber Cancer Institute provide the first details of the cancer cell machinery that carries out the hormone’s relentless growth orders.The study, to be published in the journal Cancer Cell on July 12, provides scientists with several inviting targets — cell proteins that snap into action in response to androgen — for future therapies. Drugs that block those proteins could slow or stifle tumor growth in many breast cancer patients who are not helped by standard hormone-blocking agents such as tamoxifen.“We identified a novel subtype of breast tumor which grows in response to androgen but not estrogen, and have uncovered the signaling pathways involved in its growth. And we’ve demonstrated that drugs capable of blocking these pathways, including the receptor for androgen itself, can inhibit tumor growth,” says Harvard Medical School Professor Myles Brown, the study’s senior author. “This opens new avenues to the treatment of some women with breast cancer that doesn’t respond to standard endocrine therapies.”About 70 to 75 percent of breast tumors are fueled by the female hormone estrogen. Their cells are loaded with estrogen receptors (ER), traplike structures specially shaped to ensnare estrogen molecules. When estrogen becomes lodged in an estrogen receptor, it sets off a chain of events that prompts the cell to grow and proliferate. Drugs such as tamoxifen block estrogen from entering the receptor, thereby thwarting the growth process.The remaining 25 to 30 percent of breast cancers, dubbed ER-negative tumors, lack estrogen receptors, and thus do not respond to tamoxifen and similar agents. Scientists know that the majority of breast tumors — even those with estrogen receptors — have receptors for androgen, but the reasons for these receptors’ presence, and how they might influence tumor growth, have been unknown.It might seem odd that some women’s breast cancers carry receptors for a hormone associated with males, but androgen is also involved in the normal development of secondary sexual characteristics in females, Brown remarks. Scientists have theorized that androgen propels the growth of breast cancer cells that have receptors for androgen but not for estrogen. The current study set out to find if that is the case and, if so, why.Using published data on the genomic make-up of breast tumor cells, Brown and his colleagues found a distinctive group — accounting for 5 to 10 percent of all breast cancer patients — that had large numbers of androgen receptors, no ERs, and an oversupply of a protein called HER2. Cells of this type proliferated rapidly when exposed to androgen.To understand the mechanism behind this growth, investigators did a mass screening of these tumor cells’ genetic material to see which sections of DNA bind to the androgen receptor — an indication of which genes the receptor directly switches on and off. By combining these findings with a survey of all the genes active within these cells, the researchers found that the androgen receptor governs two “transmission lines” — or pathways — for growth signals. The pathways, named for important proteins within them (WNT and HER2), play central roles in cell division and proliferation.When researchers used drugs to handcuff the androgen receptor or the WNT or HER2 proteins in ER-negative breast cancer cells, tumor growth slowed — both in laboratory cell cultures and in mice grafted with the cells.“These findings are strong evidence that therapies that shut down proteins in the WNT or HER2 pathways, or block the androgen receptor itself, can be effective anti-tumor agents for women with this variety of breast cancer,” Brown says. “Combination therapies that target proteins at different points in the pathways are likely to have the greatest success.”The study involved a close collaboration between Brown’s lab and the computation biology group at Dana-Farber headed by X. Shirley Liu, an associate professor of biostatistics at Harvard School of Public Health. Brown and Liu recently founded the Dana-Farber Center for Functional Cancer Epigenetics in order to make the genomic and computational approaches used in this study more widely available to the scientific community.The co-first authors of the study are Min Ni and Yiwen Chen of Dana-Farber. Co-authors include Elgene Lim, Shannon Bailey, and Yuuki Imai of Dana-Farber; and Hallie Wimberly and David Rimm of Yale University School of Medicine.The study was supported by grants from the National Cancer Institute, National Institutes of Health, and Department of Defenselast_img read more

first_imgAdvertisement Loading… Ndidi and Perez did not feature in either of City’s first two behind-closed-doors friendlies against Championship sides Birmingham and Sheffield Wednesday but are now back in action. read also:Let’s approach new season with renewed desire, determination, Rodgers urges Ndidi, others Maddison and Fuchs’ returns represent good news on the injury front. Attacking midfielder Maddison underwent minor hip surgery in July, and was expected to be fit for the start of pre-season training. Last week, however, he was in the gym with Ricardo Pereira, rather than training with his team-mates. Now, he looks to be back in full training. FacebookTwitterWhatsAppEmail分享 Four Leicester City stars have been pictured back in training as the club edges closer to a full complement of players. Wilfred Ndidi, Ayoze Perez, James Maddison, and Christian Fuchs were all on the pitch at Belvoir Drive on Thursday as the squad continued their preparations for this Saturday’s preseason game against Blackburn, and the Premier League opener at West Brom that follows eight days later. Promoted ContentPlaying Games For Hours Can Do This To Your Body5 Of The World’s Most Unique Theme ParksThe Highest Paid Football Players In The World7 Mind-Boggling Facts About Black HolesProbably The World’s Most Beautiful Ceilings!The Very Last Bitcoin Will Be Mined Around 2140. Read MoreWhich Country Is The Most Romantic In The World?Who Is The Most Powerful Woman On Earth?10 Risky Jobs Some Women Do10 Extremely Dirty Seas In The WorldA Guy Turns Gray Walls And Simple Bricks Into Works Of Art10 Irresistibly Beautiful Asian Actresseslast_img read more

first_imgPhoto: © pixabay.com The Willie Mullins-trained Brahma Bull will look to make it four-wins from four starts at Thurles this afternoon.The Ruby Walsh mount makes his debut over hurdles in the Maiden Hurdle there this afternoon.The first of a seven-race card at Thurles went to post at five-to-1.last_img